Glivec(R) should not be interrupted in patients with advanced GIST
A study of 192 patients with advanced gastrointestinal stromal tumor (GIST) found that Glivec(R) interruption was associated with a high risk of re-progression. In contrast, continuous treatment showed no signs of re-progression within a year. Continuous Glivec(R) treatment is recommended for patients with advanced GIST.